文献速递肿瘤 PET/CT

在普通肿瘤 PET/CT 人群中定量评估肿瘤活性:哪种指标最能减少示踪剂摄取时间依赖性

Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence?
PubMed 文献 · J Nucl Med · 2024-09-03

这项前瞻性单中心研究纳入 78 名接受标准诊疗肿瘤 PET/CT 的成人,分析 41 名受试者 116 个病灶。结果显示,与 SUVmax 和 SURmax 相比,Ki,max、cSUVmax 和 cSURmax 的摄取时间依赖性较低,且 cSURmax 可预测 Ki,max。

要点

  • SUVmax 和 SURmax 从早期到晚期大幅升高,扫描内重复性差。
  • 在 [18F]FDG 和 DOTATATE 病灶中,Ki,max、cSUVmax 和 cSURmax 的扫描内重复性无显著差异。
  • Ki,max、cSUVmax、cSURmax 与 Ki,max 强相关,cSURmax 与 Ki,max 一致性最佳。

核心结论

  • 与 SUVmax 和 SURmax 相比,Ki,max、cSUVmax 和 cSURmax 的摄取时间依赖性较低。
  • Ki,max 可由 cSURmax 预测。

研究设计与样本

  • 前瞻性单中心研究,纳入接受标准诊疗肿瘤 PET/CT 的成人。
  • 共入组 78 名受试者,最终分析 41 名受试者(平均年龄 63.8 岁;24 名男性)的 116 个病灶。
  • 从注射后约 35-50 分钟(早期)和约 75-90 分钟(晚期)的动态 PET 数据重建 SUV 和 Ki 图像,手动分割肿瘤并提取定量指标。
  • 以注射后 60 分钟为参考摄取时间计算 cSUV 和 cSUR。
  • 计算扫描内重测百分比变化绝对值、决定系数(R²)和组内相关系数(ICC),采用 Wilcoxon 符号秩检验(α=0.05)比较指标间差异。

主要发现

  • 对于两种示踪剂,SUVmax 和最大 SUR(SURmax)从早期到晚期均大幅升高,扫描内重复性差。
  • 在 [18F]FDG 高摄取病灶(n=93)中,Ki,max 与 cSUVmax 或 cSURmax 的扫描内重复性无差异:中位重测|%Δ| 分别为 Ki,max 13%、cSUVmax 12%(P=0.90)、cSURmax 13%(P=0.67);ICC 分别为 0.97、0.96、0.94。
  • 在 DOTATATE 高摄取病灶(n=23)中,Ki,max 与 cSUVmax 或 cSURmax 的扫描内重复性无差异:中位重测|%Δ| 分别为 Ki,max 11%、cSUVmax 13%(P=0.41)、cSURmax 11%(P=0.08);ICC 分别为 0.98、0.98、0.94。
  • SUVmax、cSUVmax、SURmax 和 cSURmax 均与 Ki,max 强相关:[18F]FDG 的 R² 为 0.81-0.92,DOTATATE 的 R² 为 0.88-0.96。
  • cSURmax 与 Ki,max 在早期到晚期时间点的一致性最佳:[18F]FDG 的 ICC 为 0.69-0.75,DOTATATE 的 ICC 为 0.90-0.91。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

In oncologic PET, the SUV and standardized uptake ratio (SUR) of a viable tumor generally increase during the postinjection period. In contrast, the net influx rate (Ki ), which is derived from dynamic PET data, should remain relatively constant. Uptake-time-corrected SUV (cSUV) and SUR (cSUR) have been proposed as uptake-time-independent, static alternatives to Ki Our primary aim was to quantify the intrascan repeatability of Ki , SUV, cSUV, SUR, and cSUR among malignant lesions on PET/CT. An exploratory aim was to assess the ability of cSUR to estimate Ki Methods: This prospective, single-center study enrolled adults undergoing standard-of-care oncologic PET/CT. SUV and Ki images were reconstructed from dynamic PET data obtained before (∼35-50 min after injection) and after (∼75-90 min after injection) standard-of-care imaging. Tumors were manually segmented. Quantitative metrics were extracted. cSUVs and cSURs were calculated for a 60-min postinjection reference uptake time. The magnitude of the intrascan test-retest percent change (test-retest |%Δ|) was calculated. Coefficients of determination (R 2) and intraclass correlation coefficients (ICC) were also computed. Differences between metrics were assessed via the Wilcoxon signed-rank test (α, 0.05). Results: This study enrolled 78 subjects; 41 subjects (mean age, 63.8 y; 24 men) with 116 lesions were analyzed. For both tracers, SUVmax and maximum SUR (SURmax) had large early-to-late increases (i.e., poor intrascan repeatability). Among [18F]FDG-avid lesions (n = 93), there were no differences in intrascan repeatability (median test-retest |%Δ|; ICC) between the maximum Ki (Ki ,max) (13%; 0.97) and either the maximum cSUV (cSUVmax) (12%, P = 0.90; 0.96) or the maximum cSUR (cSURmax) (13%, P = 0.67; 0.94). For DOTATATE-avid lesions (n = 23), there were no differences in intrascan repeatability between the Ki ,max (11%; 0.98) and either the cSUVmax (13%, P = 0.41; 0.98) or the cSURmax (11%, P = 0.08; 0.94). The SUVmax, cSUVmax, SURmax, and cSURmax were all strongly correlated with the Ki ,max for both [18F]FDG (R 2, 0.81-0.92) and DOTATATE (R 2, 0.88-0.96), but the cSURmax provided the best agreement with the Ki ,max across early-to-late time points for [18F]FDG (ICC, 0.69-0.75) and DOTATATE (ICC, 0.90-0.91). Conclusion: Ki ,max, cSUVmax, and cSURmax had low uptake time dependence compared with SUVmax and SURmax The Ki ,max can be predicted from cSURmax.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Ince S, Laforest R, Itani M, et al. Quantitative Assessments of Tumor Activity in a General Oncologic PET/CT Population: Which Metric Minimizes Tracer Uptake Time Dependence? J Nucl Med. 2024. PMID: 39142828. doi:10.2967/jnumed.123.266469

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。